Clinical trial
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Name
PBC016
Description
This is a single arm study to evaluate the efficacy and safety of CD123-targeted CAR-T cells therapy for patients with relapsed/refractory Acute Myeloid Leukemia.
Trial arms
Trial start
2019-12-01
Estimated PCD
2023-12-31
Trial end
2024-07-01
Status
Recruiting
Phase
Early phase I
Treatment
CD123 CAR-T cells
A single infusion of CD123-CAR-T cells will be administered intravenously
Arms:
CD123 CAR-T cells treat
Size
40
Primary endpoint
Adverse events that related to treatment
2 years
The response rate of CD123 CAR-T treatment in patients with relapse/refractory Acute Myeloid Leukemia that treatment by CD123 CAR-T cells therapy
6 months
Eligibility criteria
Inclusion Criteria:
1. Signed written informed consent;
2. Diagnose as relapsed /refractory acute myeloid leukemia, and meet one of the following conditions:
1. Failed to standard chemotherapy regimens;
2. Relapse after complete remission, high-risk and / or refractory patients ;
3. Relapse after hematopoietic stem cell transplantation;
3. Evidence for cell membrane CD123 expression;
4. All genders, ages: 3 to 75 years;
5. The expect time of survive is above 12 weeks;
6. KPS\>60;
7. No serious mental disorders ;
8. Left ventricular ejection fraction ≥50%
9. Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN;
10. Sufficient renal function defined by creatinine clearance≤2 x ULN;
11. Sufficient pulmonary function defined by indoor oxygen saturation≥92%;
12. With single or venous blood collection standards, and no other cell collection contraindications;
13. Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Exclusion Criteria:
1. Have received CAR-T therapy or other genetically modified cell therapy before screening;
2. Participated in other clinical research within 1 month before screening;
3. Have received the following anti-tumor treatment before screening: Have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment;
4. Live attenuated vaccine within 4 weeks before screening;
5. Convulsion or stoke within past 6 months;
6. Previous history of other malignancy;
7. Presence of uncontrolled active infection;
8. Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive and peripheral blood HCV RNA titer is higher than the lower limit of detection of the research institution; HIV antibody positive; syphilis primary screening antibody positive;
9. Pregnant or breasting-feeding women;
10. Any situation that investigators regard not suitable for attending in this study or may affect the data analysis.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}
Updated at
2023-04-18
1 organization
1 product
3 indications
Organization
Chongqing Precision BiotechProduct
CD123 CAR-T cellsIndication
LeukemiaIndication
myeloidIndication
Acute